Regeneron’s Gene Therapy Improves Auditory Responses in Children with Genetic Hearing Loss
Regeneron’s trial investigating otoferlin gene therapy (DB-OTO) represents it’s first auditory program and is currently enrolling patients.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
